SBIR/STTR Research Award

SBIR Phase I: A Nanofluidic Instrument for High-throughput Single-molecule Analysis

Award identifier 8d02c8ed68f56993ea458dffec532ddf1420babda196bcc82997831e8126e4fcAwarding agency National Science Foundation

Award amount

$150,000

Program and phase

SBIR · Phase I

Award year

2012

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
Odyssey Scientific, Inc.
Proposal award date
2012-01-01
Contract end date
2012-12-31
UEI
Not reported
Solicitation number
Not reported
Topic code
BC

Research abstract

This Small Business Innovation Research (SBIR) Phase I project aims to develop a commercial nanofluidic chip for the rapid identification of epigenetic marks on individual molecules. The instrument will dramatically improve existing methods of epigenomic analysis by removing two major limitations of the current technology. The proposed device will enable automated quantification of multiple epigenetic marks simultaneously using minute inputs of chromatin and high throughput single molecule observations. The approach involves measuring distinct fluorescent signals from antibodies bound specifically to epigenetic marks on individual chromatin fragments that are electrophoretically transported through lasers focused within a nanoscale fluidic channel. The objectives of this proposal are to transform this laboratory setup into a prototype commercial product by increasing the throughput using parallel fluidic channels and transforming to a free space optical system. It is anticipated that this Phase I proposal will result in the fabrication of devices containing 96 parallel nanofluidic channels and the design of the free space optical system that will facilitate this transformation. The broader impact/commercial potential of this project is that it will result in commercially available products that overcome two key limitations of current epigenomic technology. Current technology requires an abundant amount of input material and can query only one epigenetic mark at a time. The proposed single molecule analytical methods can overcome both of these limitations. It is anticipated that this effort will yield a new disruptive epigenomics technology to serve commercial, academic, and clinical needs. By developing an automated instrument that can interrogate multiple epigenetic marks simultaneously on single chromatin molecules extracted from very small inputs of cells, this technology will enable epigenomic analyses that are far more information rich and lower in cost than is currently possible.

Technology keywords

Not reported

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.